Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.71 - $13.6 $17,750 - $340,000
-25,000 Reduced 55.56%
20,000 $13,000
Q2 2022

Aug 15, 2022

SELL
$0.62 - $1.94 $9,300 - $29,100
-15,000 Reduced 25.0%
45,000 $33,000
Q1 2022

May 16, 2022

SELL
$1.59 - $3.16 $23,850 - $47,400
-15,000 Reduced 20.0%
60,000 $112,000
Q3 2021

Nov 15, 2021

BUY
$3.43 - $5.63 $257,250 - $422,250
75,000 New
75,000 $383,000

Others Institutions Holding APRE

About Aprea Therapeutics, Inc.


  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.